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ABSTRACT
Objective To describe patterns of anticoagulation 
prescription and persistence for those aged ≥65 years with 
atrial fibrillation (AF).
Methods Descriptive cohort study using electronic 
general practice records of patients in England, who 
attended an influenza vaccination aged ≥65 years 
and were diagnosed with AF between 2008 and 2018. 
Patients were stratified by 10- year age group and 
year of diagnosis. Proportion anticoagulated, type of 
anticoagulation (direct oral anticoagulant (DOAC) or 
warfarin) initiated at diagnosis and persistence with 
anticoagulation over time are reported.
Results 42 290 patients (49% female), aged 65–74 
(n=11 722), 75–84 (n=19 055) and 85+ (n=11 513) 
years at AF diagnosis are included. Prescription of 
anticoagulation at diagnosis increased over the time 
period from 55% to 86% in people aged 65–74 years, 
from 54% to 86% in people aged 75–84 years and from 
27% to 75% in people aged 85 years and over. By 2018, 
92% of patients with newly diagnosed AF were started 
on a DOAC. Survivor function for 5- year persistence in 
patients prescribed DOAC was 0.80 (95% CI 0.77 to 0.82) 
and for warfarin 0.71 (95% CI 0.70 to 0.72). Survivor 
function for any anticoagulation at 5 years was 0.79 (95% 
CI 0.78 to 0.81), 0.73 (95% CI 0.72 to 0.75) and 0.58 (95% 
CI 0.59 to 0.64) for people aged 65–74, 75–84 and 85+ 
years, respectively.
Conclusions Rates of anticoagulation in AF in those 
aged ≥65 years have increased from 2008 to 2018, over 
which time period there has been a shift from initiating 
anticoagulation with warfarin to DOAC. Persistence with 
anticoagulation is higher in people on DOACs than on 
warfarin and in people aged <85 years.
INTRODUCTION
Atrial fibrillation (AF) is an independent risk 
factor for stroke. Incidence of AF increases 
from 6 per 1000 in those aged 60–69 years to 
39 per 1000 in those aged 80–89 years. Thir-
ty- one per cent of strokes in those aged 80–89 
years may be attributed to AF, compared with 
7.3% in those aged 60–69.1
Oral anticoagulation reduces the risk of 
stroke by 65%. Although use is increasing, 
it is still underused in the UK, with 22% of 
eligible patients not receiving treatment in 
2018.2 3
Warfarin, a vitamin K antagonist, was the 
first oral anticoagulant available and was 
licenced in the USA in 1954. Dabigatran was 
the first of the direct oral anticoagulation 
(DOAC) medications licensed for use in the 
UK in 2008. This has been followed by others 
in this group, including rivaroxaban, apix-
aban and edoxaban. Their arrival has been 
associated with an increase in prescribing of 
anticoagulation in non- valvular AF for all age 
groups.4
Key questions
What is already known about this subject?
 ► Anticoagulation is a highly effective way of reducing 
the risk of stroke associated with atrial fibrillation 
(AF), but is underused, particularly in older people.
 ► The introduction of direct oral anticoagulant (DOAC) 
has been associated with increasing use of antico-
agulation in AF.
 ► The UK National Screening Committee has stated 
that insufficient evidence about anticoagulation 
prescribing patterns, compliance and persistence 
is one of the barriers to a national screening pro-
gramme for AF.
What does this study add?
 ► Our study provides up- to- date information on an-
ticoagulation for AF in older people who are most 
at risk of AF- related stroke and highlights particular 
increases in use of anticoagulation in people aged 
85 years and over.
 ► DOACs are now the major class of anticoagulant 
prescribed to patients with new AF in UK general 
practice.
 ► Long- term persistence with anticoagulation is high-
er with DOACs than warfarin, but drops in all age 
groups over 5 years.
How might this impact on clinical practice?
 ► Improved uptake of anticoagulation at all ages re-
moves one of the potential barriers to screening for 
AF, but new strategies may be needed to enhance 
long- term persistence with treatment.
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Since risk of stroke in AF rises with age, the potential 
benefit from anticoagulation also rises with age, although 
so do risk of bleeding complications.5 The National Insti-
tute for Health and Care Excellence guidance recom-
mends the use of anticoagulation in all those with a 
CHA2DS2VASC2 score of 2 or more and the consideration 
of anticoagulation in those with a score of 1 where this 
is not due to gender, which means all patients aged ≥65 
years with AF are potential candidates for anticoagula-
tion, and all patients aged ≥75 years should be offered 
such treatment. Historically, older people have been less 
likely to receive anticoagulation despite evidence that the 
potential benefit is greater than the risk.6
AF has been considered as a candidate for a national 
screening programme in the UK. One of the criteria for 
adopting screening is that the clinical management of the 
condition should be optimised prior to implementation 
of screening.7 The UK National Screening Committee 
reviewed patterns of anticoagulation prescribing for AF 
in 2019. It concluded that there was insufficient evidence 
of optimised compliance, and around prescribing 
patterns of anticoagulation in AF, in part because of lack 
of evidence about anticoagulation persistence over time.8
The objective of this study is therefore to provide this 
evidence of patterns of anticoagulation prescribing and 
persistence by 10- year age group over the age of 65 years.
We answered three research questions using an elec-
tronic primary care database study:
1. How has the proportion of people with AF aged over 
65 years who are anticoagulated changed between 
2008 and 2018?
2. How has the type of anticoagulant prescribed changed 
for people with incident AF?
3. How is anticoagulation persistence over the age of 65 
years affected by age and type of anticoagulation?
METHOD
Data and population
Data were extracted from the Clinical Practice Research 
Datalink (CPRD), a primary care research database of 
anonymised, electronic coded records from the Vision 
computer system.9 All clinical activity (including diag-
noses and prescribing) in primary care are recorded 
using clinical codes. The dataset on which these analyses 
were performed was originally extracted to explore the 
impact of case finding for AF at the time of influenza 
vaccination. Influenza vaccination is offered to everyone 
over the age of 65 years in the UK, and uptake in this age 
group over the time period of the study was 71%–75%.10
Patients included in this study were registered with a 
general practitioner (GP) in England, had records which 
fulfilled CPRD data quality standards,9 had a first diag-
nosis of AF between 1 September 2008 and 31 August 
2018 and attended at least one influenza vaccine after the 
age of 65 years and during the study period, with at least 
1- year registration before their first eligible influenza 
Figure 1 Patient flow diagram. AF, atrial fibrillation; CPRD, Clinical Practice Research Datalink; GP, general practitioner; UTS, 
up to standard: CPRD defined criteria for data quality;9 TOD, transfer out date :Date at which patients transfer to another 
practice.
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vaccination. For each patient, follow- up started at the 
date of first recorded AF diagnosis and ended when the 
patient left the GP practice or died, the practice stopped 
contributing data to CPRD, or 31 August 2018, whichever 
was earliest. Further limited exclusions for data quality 
were made; patients with an AF diagnosis recorded >30 
days after the end of follow- up were excluded. Details 
of patient selection, inclusion and exclusion criteria are 
given in figure 1.
Definitions of AF and anticoagulation
We analysed cases of AF diagnosed each year from 1 
September 2008 to 31 August 2018.
The date and type of first anticoagulation are defined 
at the first record of an oral anticoagulant prescription. 
For all analyses, we defined an anticoagulation prescrip-
tion as a medication from the prespecified list (online 
supplemental appendix 1) with a tablet quantity greater 
than zero.
Lists of codes which record AF diagnoses and anticoag-
ulation prescribing are available in online supplemental 
data appendix 1.
Demographic and clinical characteristics
We defined three age groups, 65–74, 75–84 and 85+ 
years. People aged 85 years and over were grouped 
because of small numbers and the risk of statistical disclo-
sure. We described the clinical characteristics of the study 
population on the day before AF diagnosis as the count 
of long- term conditions (out of the 20 included in the 
Cambridge multimorbidity score).11 Deprivation was 
defined as the index of multiple deprivation (IMD) score 
of the GP practice attended by each cohort member, 
linked and provided by CPRD. IMD score is a small area 
measure of deprivation, measured across seven domains 
and reported for 32 844 small areas in England.12
Analyses
In our first analysis, we explored changes in the propor-
tion of people with AF prescribed anticoagulation by age 
and year. Each cohort was defined by age group at diag-
nosis and 2- year diagnosis interval. Patients were included 
in the denominator of each 2- year time point analysis if 
they had contributed data at any point during the 2- year 
time interval and were defined as anticoagulated if they 
had received any prescription of anticoagulation in this 
time.
For our second analysis, we included incident AF cases 
who received anticoagulation within 365 days of diagnosis 
and calculated the proportion, with 95% CIs, of these, 
stratified by age group, who received a DOAC as the first 
prescription after AF diagnosis. For this analysis, patients 
contributed to both the numerator and denominator of 
any year if they had a minimum of 365 days of follow- up 
after AF diagnosis.
In our final analyses, we described the time to end 
of anticoagulation use, stratified by age group at diag-
nosis and by age and type of anticoagulation. Analysis 
entry point was defined as the later of AF diagnosis date 
or first anticoagulation prescription date. The date of 
end of anticoagulation is defined as the date of the last 
anticoagulation prescription if this is >90 days before 
leaving the sample. If the patient left the sample for any 
reason within 90 days of anticoagulation prescription, 
they were censored at the leaving date. For this analysis, 
type of anticoagulation was defined as one of four cate-
gories; warfarin only, DOAC only, warfarin changed to 
Figure 2 Anticoagulation for atrial fibrillation (AF) by cohort; age and year of diagnosis.
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DOAC during follow- up and DOAC changed to warfarin. 
Patients with a prescription for a vitamin K antagonist 
other than warfarin were excluded due to small numbers. 
The survivor function was calculated, with 95% CIs, at the 
5- year time point for all age and medication cohorts.
All data analysis was completed using STATA software 
V.16.13 There was no patient or public involvement in this 
project.
RESULTS
There were 42 290 patients with newly recorded AF during 
the study. At diagnosis, 28% (11 722)), 45% (19 055) and 
27% (11 513) of patients were aged 65–74, 75–84 and 85+ 
years, respectively; 49% (20 850) of patients in the total 
sample were female. The proportion of new cases diag-
nosed in female patients rose from 39% (4583) in the 
65–74 years age group to 61% (6994) in the over 85 years 
age group;. 35% (14861) of cases were diagnosed in those 
with four or more pre- existing comorbidities, falling to 
6% (2492) in those with no other comorbidities with no 
systematic variation by deprivation. Across all age groups, 
there were falling numbers of cases in the later years of 
the study, this represents the falling number of practices 
contributing to CPRD using the Vision computer soft-
ware over this time period (table 1).
Both cohort and period effects are seen in the prescrip-
tion of anticoagulation over the 10 years of the study. For 
all age groups, the proportion of patients anticoagulated 
at the time of diagnosis increased between 2008 and 2018 
(figure 2, table 2). This change is most marked in those 
aged 85+ years, where there was a rise from 27% (679) in 
2008–2010 to 74% (865) in 2016–2018. During the same 
time period, anticoagulation for the 65–74 years age 
group rose from the higher baseline of 55% (1482) to 
86% (937), and for the 75–84 years age group from 54% 
(2339) to 86% (1430). The difference in the proportion 
of those anticoagulated between the oldest and youngest 
age groups narrowed considerably over the 10- year 
period, from 28% to 11%. Within each age and year of 
diagnosis cohort, there is also a consistent upward trend 
in the proportion who are anticoagulated over time. For 
example, in those aged 85+ years during 2008–2010 the 
proportion anticoagulated at diagnosis was 27% (679). 
By 2016–2018, of those who remained in this cohort, now 
aged 95+ years, 55% (56) are receiving treatment.
No patients diagnosed with AF in 2008/2009 were 
prescribed a DOAC, but by 2017/2018, 70% (1222) 
received a DOAC within 1 year of diagnosis (figure 3). 
DOACs represented 92% (1222/1319) of first antico-
agulant prescriptions for AF in 2017/18. The use of 
DOACs increased rapidly in all age groups, with the 
largest increases seen between 2012 and 2016. The rate of 
increase was initially highest in the 85+ years age group. 
There was no significant difference between age groups 
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A total of 29 644 patients received a prescription for 
oral anticoagulation at any time point following AF diag-
nosis. Of these, 60% (17 753) received only warfarin, 28% 
(8351) only DOAC, 11% (3298) switched from warfarin 
to DOAC during the study period and 1% (246) changed 
from DOAC to warfarin. Due to the small number of 
patients who changed from DOAC to warfarin, these 
patients were excluded from further analysis (table 3).
Persistence with anticoagulation was high across all 
age groups, with the greatest rate of decrease in the first 
year (figure 4). Anticoagulation persistence was higher 
in the younger age groups at all time points. At 5 years, 
the survivor function for anticoagulation was 0.79 (95% 
CI 0.78 to 0.81) in those aged 65–74 years, 0.73 (95% CI 
0.72 to 0.75) in those aged 75–84 years and 0.58 (95% CI 
0.54 to 0.61) in those aged 85+ years.
Of those who received a single type of anticoagula-
tion, persistence was highest in those prescribed a DOAC 
(figure 5). At 5 years, the probability of continuing 
Figure 3 The proportion of first anticoagulation prescriptions for newly diagnosed atrial fibrillation (AF) that are for a direct oral 
anticoagulant.
Table 3 Type of anticoagulation by age
Age at diagnosis 65–74 75–84 85+ All ages
DOAC only 2379 3761 2211 8351
Warfarin only 5653 8831 3269 17 753
Warfarin changed to DOAC 1125 1646 527 3298
DOAC changed to warfarin 78 125 43 246
Figure 4 Anticoagulation persistence by age.
7Lund J, et al. Open Heart 2021;8:e001737. doi:10.1136/openhrt-2021-001737
Arrhythmias and sudden death
anticoagulation for those only prescribed a DOAC was 
0.79 (95% CI 0.77 to 0.82) compared with 0.71 (95% 
CI 0.71 to 0.76) in those only prescribed warfarin. If 
all patients initially prescribed warfarin are considered, 
including those who subsequently switched to a DOAC, 
then 5- year probability of continuing anticoagulation was 
0.75 (95% CI 0.740.76).
DISCUSSION
Summary
Anticoagulation has increased across all age groups from 
2008 to 2018 with the greatest rise in those aged over 85 
years. There have been both cohort and period effects 
with regard to prescription of anticoagulation. Increases 
are greatest in those with newly diagnosed AF. DOACs 
now represent the vast majority of anticoagulant prescrip-
tions offered to all patients aged over 65 years with newly 
diagnosed AF. Anticoagulation persistence decreases with 
age, being lowest in those aged over 85 years. Persistence 
is higher in those prescribed DOACs as compared with 
warfarin.
Strengths and limitations
The major strength of this study is the large sample size 
and generalisability to the UK population. Ours is the 
first study to tease out period from cohort effects in anti-
coagulation prescribing in this age group. As with all elec-
tronic record studies a major limitation is the reliance on 
recorded, coded, diagnoses. It is possible that patients 
receiving anticoagulation are more likely to have a coded 
diagnosis of AF and therefore the incidence of anticoagu-
lation seen in this paper may be artificially elevated.
Inclusion of only patients who have had an influ-
enza vaccination may mean that the cohort of patients 
described in this study are those more likely to attend for 
healthcare and therefore more likely to receive anticoag-
ulation. However, the AF incidence seen is comparable 
to that reported using all CPRD records.14 These poten-
tial biases are unlikely to have had any major effect on 
the observed trends, since their magnitude will not have 
changed substantially over the time period of the study.
A further limitation is the use of anticoagulant 
prescription issues as a marker for persistence with medi-
cation. It is possible that prescriptions are issued without 
Figure 5 Anticoagulation persistence by age and type. Due to small patient numbers those who have transferred from direct 
oral anticoagulant (DOAC) to warfarin are not presented.
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medication being taken, particularly considering the 
move toward electronic repeat dispensing in the UK.
We have shown that anticoagulation goes up over time 
in all age groups. This is likely in part due to increased 
use of anticoagulation but may also represent differential 
survival in those who are anticoagulated.
Comparison with existing literature
The trends in overall anticoagulation and the use of 
DOAC as the anticoagulant of choice we present are 
consistent with previous UK studies.4 15 Our work brings 
these results up to date and presents new data with regard 
to age stratification for those aged over 65 yers.
We show that people who were started on a DOAC 
tend to persist longer than those on warfarin; however, 
there may be both patient selection and time effects. 
DOACs were initiated in later years than warfarin and 
there has been, over the period of the study, increased 
knowledge and awareness of the importance of persisting 
with anticoagulation. What we have observed is similar 
to the persistence seen in a recent meta- analysis where 
pooled persistence with DOACs was higher than vitamin 
K antagonists (OR 1.44),16 although many of the studies 
included within this have a significantly shorter period 
of follow- up. Anticoagulation persistence is known to 
be lower in younger age groups,17 18 our patients were 
older, mean age 80 years, than in any of the studies 
included in the systematic review and this may partially 
explain the high overall persistence seen. In clinical trials 
where randomisation eliminates patient selection bias, 
there was no clear pattern of superiority of DOAC over 
warfarin.19–21 Our study is observational and therefore we 
cannot be sure of the effects of patient selection bias. The 
choice of anticoagulant is largely an individual decision 
made between clinician and patient and there may be 
an unmeasured characteristic that affects the choice of 
medication and the likelihood of persistence.
Implications for research policy and practice
Our results show there has been a major shift in the use of 
anticoagulation in the UK. DOACs have become the first- 
line anticoagulant for those with AF and are being used 
in ever increasing numbers of patients, including large 
numbers aged over 85 years. We provide some circum-
stantial evidence to support the success of initiatives to 
increase uptake of anticoagulation.22 This suggests that 
poor uptake of anticoagulation may no longer be a 
barrier to screening for AF.
We note that the high levels of anticoagulant prescribing 
that we observed are against a background of multimor-
bidity, which would be expected to increase the poten-
tial iatrogenic effects of anticoagulation prescribing, as 
multimorbidity increases risk of haemorrhage.23
Those prescribed warfarin require frequent moni-
toring and dose adjustment. Currently, there are multiple 
models of care as to how this service is provided, across 
both primary and secondary care. As the number 
of patients receiving warfarin continues to decline, 
consideration will need to be given to the best model of 
care for continuation of specialist warfarin services for 
the small number of patients who continue to use it. This 
will need to account for the likely older age profile of 
these patients.
A final consideration is that the current data are all 
drawn prior to the COVID-19 pandemic. As a result of the 
pandemic, UK guidance, endorsed by the Royal College 
of General Practitioners, has encouraged the accelerated 
switching of warfarin to DOAC for patients with AF to 
avoid unnecessary trips to healthcare settings for moni-
toring.24 Pandemic guidance from NHS England explic-
itly recommends that patients newly diagnosed with AF 
are offered a DOAC in preference to warfarin. There-
fore, the trends seen in this paper may well have acceler-
ated in 2020.
CONCLUSION
The use of anticoagulation for AF has increased over the 
period 2008–2018, with the greatest increases seen in 
those aged over 85 years, both in terms of initiation and 
persistence than previously reported. DOACs now repre-
sent the vast majority of anticoagulation prescriptions for 
newly diagnosed AF. This study provides some evidence 
that DOACs are associated with higher long- term persis-
tence in older adults than warfarin.
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